American Academy

InnoCare Releases 2023 Results and Business Highlights

Retrieved on: 
Thursday, March 28, 2024
Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Genetics, Clinical Trials, QD, Tafasitamab, Patient, B-cell lymphoma, NDA, SLE, POC, IND, Clinical trial, Bone marrow, IKZF1, Phase, Therapy, IGA, MCD, Dexamethasone, MCL, Neuromyelitis optica spectrum disorder, IKZF3, AML, NMOSD, Outline of health sciences, DLT, Cancer, Autoimmune disease, Safety, TYK2, HSA, NRDL, BLA, Follicular lymphoma, Food, GC, Development, Multiple sclerosis, PD, CRBN, Public, Gordon Ramsay's Bank Balance, Multiple myeloma, ITP, BCL2, Leukemia, Cmax, Gadolinium, HKEX, SRI, AAD, Proteinuria, DLBCL, Glucocorticoid, IVIG, Loss, European Hematology Association, American Academy, EHA, Lenalidomide, NHL, Non-Hodgkin lymphoma, CCR8, US FDA, BTK, NRS, Pharmaceutical industry

InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on cancer and autoimmune diseases, today announced the 2023 annual results as of 31 December 2023.

Key Points: 
  • InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on cancer and autoimmune diseases, today announced the 2023 annual results as of 31 December 2023.
  • In 2023, InnoCare has continued to advance its robust pipeline across various clinical stages, continuously unleashing the power of innovation to meet unmet medical needs.
  • In June 2023, the ITP Phase II result was orally presented at the European Hematology Association (EHA) 2023 Hybrid Congress.
  • InnoCare was approved by the Hong Kong Stock Exchange to remove "B" from the stock code from May 12, 2023.

The Standard Announces Retirement of Sally Manafi; Lauren Canfield Named New Corporate Actuary and Chief Risk Officer

Retrieved on: 
Wednesday, March 27, 2024
Fintech, Professional Services, Insurance, Finance, Risk management, Society of Actuaries, The Standard, Retirement, American Academy, University, Bank statement, Mathematics, Investment, Standard Insurance Company, Music, Standard, Multimedia, StanCorp Financial Group, Corporation, Management

Standard Insurance Company ( The Standard ) announced today that Lauren Canfield, assistant vice president and actuary in Actuarial Transformation, will become vice president, corporate actuary and chief risk officer effective April 1, 2024.

Key Points: 
  • Standard Insurance Company ( The Standard ) announced today that Lauren Canfield, assistant vice president and actuary in Actuarial Transformation, will become vice president, corporate actuary and chief risk officer effective April 1, 2024.
  • Canfield will succeed Sally Manafi, vice president, corporate actuary and chief risk officer, who previously announced her decision to retire.
  • View the full release here: https://www.businesswire.com/news/home/20240327644713/en/
    Sally Manafi, Retiring Vice President, Corporate Actuary and Chief Risk Officer at The Standard (Photo: Business Wire)
    “In her previous roles, Lauren provided key actuarial consultation and insight on financial and capital forecasting, investments and across multiple product lines.
  • As vice president, corporate actuary and chief risk officer for StanCorp Financial Group, Inc., Standard Insurance Company and The Standard Life Insurance Company of New York, Canfield will be responsible for enterprise risk management, asset liability management and economic capital management.

Aura Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights

Retrieved on: 
Wednesday, March 27, 2024
Oncology, FDA, Health, Clinical Trials, Pharmaceutical, Biotechnology, NMIBC, Research, Melanoma, Growth, Disease, SPA, Incidence, Paratriathlon, Inflammation, Patient, Necrosis, Travel, Light, Aes, American Academy, Cancer, Șaeș, Bladder cancer, Radiation, Eye, Doctor of Philosophy, MIBC, Visual acuity, Neoplasm, ILS, Aura, Safety, Recurrence, AAO, Annual general meeting, Food, Pharmaceutical industry

Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing precision immunotherapies to treat solid tumors to preserve the function of the afflicted organ with cancer, today reported financial results for the fourth quarter and year ended December 31, 2023, and provided recent business highlights.

Key Points: 
  • Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing precision immunotherapies to treat solid tumors to preserve the function of the afflicted organ with cancer, today reported financial results for the fourth quarter and year ended December 31, 2023, and provided recent business highlights.
  • The primary endpoint is time to tumor progression when the last patient completes 15 months of follow up.
  • As of December 31, 2023, Aura had cash and cash equivalents and marketable securities totaling $226.2 million.
  • General and administrative expenses include $1.2 million and $1.1 million of stock-based compensation for the three months ended December 31, 2023 and 2022, respectively.

World-Renowned Ancient DNA Expert, HHMI Investigator, and MacArthur Award Winner Beth Shapiro, Ph.D., Joins Colossal as Chief Science Officer

Retrieved on: 
Tuesday, March 19, 2024
Environment, Research, Genetics, Environmental Issues, Environmental Health, Biotechnology, Health, Other Science, Science, Genomics, Gene, Executive Committee, National Geographic Explorer, Woolly mammoth, Cell, University, Pennsylvania State University, Television, Life, DNA, Stanford University, CRISPR, Ice, Vertebrate Genomes Project, Hologenomics, Genome, HHMI, Colossal Biosciences, Balliol College, Oxford, Howard Hughes Medical Institute, Ecology and Evolutionary Biology, CSO, Domestication, Natural history, National academy, American Academy, Biology, Searle, George Church, Multimedia, MacArthur Fellows Program, Hunting

Colossal Biosciences, the world’s first de-extinction company, today announced that Beth Shapiro, Ph.D. , internationally renowned evolutionary molecular biologist, leader in paleogenomics, and ancient DNA expert, has joined as Chief Science Officer.

Key Points: 
  • Colossal Biosciences, the world’s first de-extinction company, today announced that Beth Shapiro, Ph.D. , internationally renowned evolutionary molecular biologist, leader in paleogenomics, and ancient DNA expert, has joined as Chief Science Officer.
  • In this role, she will oversee the continued expansion of the company’s de-extinction and conservation science teams.
  • A MacArthur “Genius Grant” Award winner and National Geographic Explorer, Beth Shapiro is a pioneer in the scientific fields of ancient DNA and paleogenomics.
  • “She’s the author of inspiring books 'How to Clone a Mammoth' and 'Life as We Made It,' plus an HHMI and MacArthur Fellow.

New York Life Names Todd Taylor Head of Life Insurance Solutions, Matt Wion Head of Retail Annuities

Retrieved on: 
Tuesday, March 19, 2024
Professional Services, Insurance, Human Resources, Finance, Retail, Society of Actuaries, Prudential, SVP, Prudential Financial, American Academy, Head, Society, Ernst & Young, IRI, Senior, Retirement, Patent, Pennsylvania State University, Binghamton University

New York Life, America’s largest mutual life insurer1, today announced that Todd Taylor has been named Head of Life Insurance Solutions, a key area of the company’s Foundational Business.

Key Points: 
  • New York Life, America’s largest mutual life insurer1, today announced that Todd Taylor has been named Head of Life Insurance Solutions, a key area of the company’s Foundational Business.
  • “As we cultivate leadership talent at New York Life, we are focused on opportunities for our team to experience different areas across the company,” said Mr. Huang.
  • Previously, Mr. Wion was Chief Financial Officer for New York Life’s Strategic Insurance Businesses – which include Institutional Life, Institutional Annuities, New York Life Direct, New York Life Group Benefit Solutions, Group Membership Association Department, and Seguros Monterrey New York Life – and has been responsible for all financial aspects for this portfolio.
  • Prior to joining New York Life, Mr. Wion was Senior Manager with Ernst & Young.

STAAR Surgical Celebrates Three Million Implantable Collamer® Lenses

Retrieved on: 
Monday, March 18, 2024
Optical, Health, Surgery, Medical Devices, ICL, Presbyopia, Patient, Iris, American Academy, EVO, Eye, Surgeon, Multimedia, Astigmatism

STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (EVO ICL™) for myopia, astigmatism and presbyopia, today announced that more than three million ICLs have been sold globally.1

Key Points: 
  • STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (EVO ICL™) for myopia, astigmatism and presbyopia, today announced that more than three million ICLs have been sold globally.1
    This press release features multimedia.
  • View the full release here: https://www.businesswire.com/news/home/20240318771746/en/
    “We extend our sincere gratitude to the surgeons and clinicians with whom we partner and to their patients who have chosen our ICLs for their vision correction as we celebrate our three million lens milestone,” said Tom Frinzi, President and CEO of STAAR Surgical.
  • “EVO ICL is the next logical step in refractive innovation with clear differentiators in patient outcomes and satisfaction.
  • Myopia (nearsightedness) is the most common refractive visual error and is a global epidemic that is expected to impact over half the world’s population by 2050.2
    1 EVO ICL accounts for approximately 2.5 million of the 3 million total ICLs sold.

Esri’s Dr. Dawn Wright Selected for 2024 US Science Envoys

Retrieved on: 
Wednesday, March 13, 2024
Green Technology, Women, Satellite, Maritime, Environment, Other Science, Transport, White House, Federal Government, Other Technology, State, Local, Sustainability, Software, Internet, Consumer, Professional Services, Science, Technology, Public Policy, Government, Data Analytics, Mentorship, Travel, Cohort, GIS, History, Artificial intelligence, American Academy, Hope, National academy, Challenger, Woman, Mariana Trench, Pacific Ocean, Literature, The arts, Challenger Deep, Management

Dawn Wright, among four distinguished scientists to serve as a new US Science Envoy in 2024.

Key Points: 
  • Dawn Wright, among four distinguished scientists to serve as a new US Science Envoy in 2024.
  • The scientists selected to participate this year make up the first all-female cohort in the history of the US Science Envoy Program.
  • Science Envoys help inform the Department of State, other US government agencies, and the scientific community about opportunities for science and technology cooperation.
  • Dawn Wright and Esri work to advance science using technology, visit esriurl.com/scicomm .

Cognito Therapeutics Announces Oral Presentation at 2024 American Academy of Neurology (AAN) Annual Meeting

Retrieved on: 
Wednesday, March 13, 2024
Biotechnology, Neurology, Medical Devices, Health, Clinical Trials, Cognito, AAN, Disease, American Academy, Therapy, CO, OLE, Annual general meeting, Pharmaceutical industry

Cognito Therapeutics , a leader in technology-based therapeutic interventions for neurodegenerative diseases, announced today that data from the open-label extension (OLE) study of Spectris™, a potential disease modifying therapy for the treatment of Alzheimer’s Disease, will be presented at the American Academy of Neurology (AAN) 2024 Annual Meeting, held April 13-18, 2024, in Denver, CO.

Key Points: 
  • Cognito Therapeutics , a leader in technology-based therapeutic interventions for neurodegenerative diseases, announced today that data from the open-label extension (OLE) study of Spectris™, a potential disease modifying therapy for the treatment of Alzheimer’s Disease, will be presented at the American Academy of Neurology (AAN) 2024 Annual Meeting, held April 13-18, 2024, in Denver, CO.
  • The OLE study was a separate 12-month protocol that followed the six-month OVERTURE randomized clinical trial, in which 83% of OVERTURE study participants enrolled.
  • The OLE enabled the evaluation of extended Spectris™ treatment over 18 months, employing a delayed-start analysis to evaluate the potential of Spectris™ as a disease modifying therapy.
  • For more information about the AAN abstract, visit https://www.aan.com/msa/Public/Events/AbstractDetails/55258 .

KalVista Pharmaceuticals Awarded UK Promising Innovative Medicine (PIM) Designation for Sebetralstat

Retrieved on: 
Tuesday, March 12, 2024
Health, General Health, Research, Pharmaceutical, Science, Biotechnology, EAMS, Patient, HAE, National Health Service, Health care, NHS, American Academy, KALV, Expanded access, Marketing, MHRA, PIM, Hereditary angioedema, Safety, AAAAI, Pharmaceutical industry

KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today announced the UK Medicines and Healthcare products Regulatory Agency (MHRA) has awarded the Promising Innovative Medicine (PIM) designation for sebetralstat, an investigational novel, oral plasma kallikrein inhibitor for the on-demand treatment of hereditary angioedema (HAE).

Key Points: 
  • KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today announced the UK Medicines and Healthcare products Regulatory Agency (MHRA) has awarded the Promising Innovative Medicine (PIM) designation for sebetralstat, an investigational novel, oral plasma kallikrein inhibitor for the on-demand treatment of hereditary angioedema (HAE).
  • The PIM is the first step in the Early Access to Medicines Scheme (EAMS) which would allow KalVista to treat patients with sebetralstat prior to receiving a Marketing Authorisation.
  • “We are proud to have sebetralstat designated as a Promising Innovative Medicine by the MHRA, which is similar to Expanded Access in the US,” said Ben Palleiko, Chief Executive Officer of KalVista.
  • KalVista recently provided phase 3 data for sebetralstat at the American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting, which displayed clinically and statistically significant results across all endpoints, and an excellent safety and tolerability profile.

KalVista Pharmaceuticals Reports Third Fiscal Quarter Results and Provides Operational Update

Retrieved on: 
Monday, March 11, 2024
Health, Pharmaceutical, Research, CFO, Patient, HAE, Health care, CBO, NDA, American Academy, KALV, Factor, MHRA, Clinical trial, Hereditary angioedema, Safety, Pharmacology, AAAAI, Fiscal year, Food, Pharmaceutical industry

(NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today provided an operational update and released financial results for the third fiscal quarter ended January 31, 2024.

Key Points: 
  • (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today provided an operational update and released financial results for the third fiscal quarter ended January 31, 2024.
  • Third Fiscal Quarter Financial Results:
    Revenue: No revenue was recognized for the three months ended January 31, 2024, or January 31, 2023.
  • The increase in R&D expenses during the quarter primarily reflects the ongoing Phase 3 KONFIDENT and KONFIDENT-S trials.
  • The decrease in the net cash and marketable securities position was due to cash consumption from operating expenses.